Amgen To Enhance Rare Disease Franchise With $27.8bn Horizon Takeover
Wins Three-Horse Race With Sanofi And J&J
The US major has announced its biggest acquisition to date in the form of a takeover that should expand its rare disease franchise and stave off concerns about internal products facing biosimilar competition.
You may also be interested in...
Now that Amgen has completed its $27.8bn acquisition of Horizon, the company can focus on how it will turn Tepezza back into a growth product and maintain momentum for Krystexxa and other assets.
Big pharma manufacturers are approaching a period that will be marked by the loss of exclusivity of many big-selling brands. All of the players are looking for ways to navigate the loss of revenues.
Amgen asked the FTC to accept its pledge not to bundle Horizon’s Tepezza or Krystexxa, while an FTC administrative law judge urged a settlement between the agency and Amgen.